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Transfusion Related Acute 
Lung Injury: A severe case 
triggered with anti-HLA 
class II antibodies in the 
recipient
ABSTRACT
Transfusion-related acute lung injury (TRALI) is a serious clinical syndrome associated with the transfusion of plasma-
containing blood components. The classic TRALI syndrome is characterized by the suddenly onset of respiratory failure 
within 2-6 hrs of the transfusion of a blood product, generally transient, resolves within 48-96 hrs spontaneously, and has 
a better prognosis. Nonetheless there is an expanded definition of TRALI syndrome up to 72 hrs, which is called delayed 
TRALI. The potential causes of TRALI can be explained by two distinct mechanism including the anti-leukocyte antibodies 
in donor plasma or in recipient plasma with the reverse mechanism, and biological response modifiers in susceptible 
individuals. This report highlights the succesful management of a classic TRALI case that was seen approximately two 
hours after the transfusion of a packed red blood cell and triggered with anti-HLA class II antibodies in the recipient with 
reverse mechanism accompanied by neutropenia together.
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Introduction
Transfusion Related Acute Lung Injury 
(TRALI), is a clinical syndrome tem-
porally related with transfusion thera-
py, can include dyspnea, respiratory 
failure, fever, chills, tachycardia and 
hypotension. (1) Although it is unlikely, 
hypertension can be seen with TRALI in 
some cases. The syndrome can range 
in severity from a mild dyspneic reac-
tion to acute pulmonary edema with 
acute respiratory distress syndrome. 
(2) In a review, an expanded definition 
of TRALI was varied according to the 
setting, duration and relation with other 
risk factors of Acute Lung Injury (ALI) 
such as classic and delayed TRALI. 
(3) The classic TRALI syndrome is an 
uncommon condition characterized by 
the suddenly onset of respiratory failure 
within 2-6 hrs of the transfusion of a 
blood product (3) and there must be no 
temporal relationship with an alternative 
risk factor for ALI. (4) It is usually caused 
by anti-leukocyte antibodies, resolves 
rapidly, and has a low mortality. Howe-
ver, in the delayed TRALI syndrome the 
symptoms of TRALI is begun 6-72 hrs 
after the transfusion and associated 
with a high mortality. These patients 
usually have other risk factors for ALI 
and do not experience the classic defi-
nition for TRALI. (3) In cases of TRALI 
occurring in the setting of transfusion 
and have an alternative risk factor for 
ALI, a designation of possible TRALI 
was added by the  Canadian Consen-
sus Conference also. (5) Based on new 
data, TRALI is now being considered 
among the three leading causes of tran-
sfusion-related morbidity and mortality 
in recent years. (6,7) The management 
of not only classic but also delayed 
TRALI is essentially supportive and 
most patients having suspected TRALI 
require mechanical ventilation. (8) Even 
if the pathophysiology of TRALI can be 
explained by two distinct mechanism, 
available evidence strongly suggests 
that leukocyte antibodies in donor pla-
sma are the predominant  mechanism 
in most cases with antibodies directed 
at HLA class I antigens in TRALI; howe-
ver in 5 % to 10 % of the cases, TRALI 
may develop as a result of antibodies in 
the recipient reacting with the donor’s 
leukocytes with the reverse mechani-
sm. (1,9,10) TRALI caused by anti HLA 
class II antibodies without simultaneous 
presence of anti-HLA class I antibodies 
have rarely been described.
In this report, we present a case of a 
classic TRALI syndrome triggered with 
anti-HLA class II antibodies in the reci-
pient with reverse mechanism accom-
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panied by neutropenia as a result of 
the administration of packed red blood 
cell. Therefore we want to define this 
potentially preventable life-threating 
condition and to emphasize our experi-
ence for its management in the light of 
the literatures. 
Case Report
A 36 yr-old multiparous (gravity 3, pari-
ty 3) woman, operated on for ileus a 
month ago, had been an operation 
again for closing ileostomy 2 days ago. 
Because her operation and postopera-
tive courses were uncomplicated, she 
was admitted to the surgical ward. On 
the second postoperative day, one unit 
of packed red blood cell (PRBC) was 
planned to correct anemia (Hemoglo-
bin [Hb] 6.2 g dl-1) by the surgeons. 
Then they started the transfusion in the 
surgical ward.  When she was operated 
on for ileus, in the preoperative and 
postoperative period 3 units of PRBC 
and 2 units of FFP (Fresh Frozen Pla-
sma) which were not leukoreduced 
were transfused totally in the surgery 
clinic without any adverse transfusion 
reactions. Two units of FFP which were 
transfused to the patient previosly were 
taken from her brother.
However approximately two hours after 
the transfusion of the PRBC, the pati-
ent complained about difficulty in bre-
athing. Peripheric oxygen saturation 
(SpO2) dropped to 84% and developed 
tachypnea. In this condition no eryt-
hema, urticaria and hematuria were 
noticeable. Afterwards, oxygen (O2) 
supplementation was required to main-
tain adequate oxygenation. At that point 
she was transferred to the intensive 
care unit (ICU) urgently with O2 supple-
mentation. Rapid clinical deterioration 
was noted with a falling O2 saturation 
(76%), hypotension (Systolic Blood Pre-
ssure [SBP]< 75 mmHg), tachycardia 
(Heart Rate [HR]> 140 beat.min-1) and 
tachypnea (frequency [f]> 35 min-1) 
in the ICU. A chest radiography, taken 
shortly after the onset of symptoms, 
showed extensive bilateral pulmonary 
infiltrates (figure 1). She developed 
severe respiratory failure (SpO2 60%, 
arterial carbon dioxide partial pressure 
[PaCO2] 26 mmHg, arterial oxygen 
partial pressure [PaO2] 47.2 mmHg, 
respiratory rate> 40 min-1) and hypo-
tension (SBP< 60 mmHg), then intuba-
tion and mechanic ventilation (MV) were 
required to maintain adequate oxyge-
nation. While intubating the patient, the 
endotracheal tube was filled with large 
amount of clear, frothy fluid and suctio-
ned repeatedly. She was connected to 
Figure 1. Chest radiography shortly after TRALI development, showing bila-
teral lung infiltration.
Figure 2. Chest radiography 3 days after the packed red blood cell transfu-
sion.
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a ventilator (Evita XL, Dräger, Medizin-
technix, Lübeck, Germany) in the SIMV 
(synchronized  intermittent mandatory 
ventilation)  mode and ventilated with 
an oxygen fraction in inspired air (FiO2) 
of 50% using a Positive end-expiratory 
pressure (PEEP) of 12 mmHg along 
with tidal volume of 6 ml.kg-1. While 
she was mechanically ventilated, the 
measured plateau pressure was 28 
cmH2O and she had a clinical ratio of 
the oxygen partial pressure (PO2) to 
FiO2 of 145 mmHg. The hypotension 
was unresponsive to iv fluid admini-
stration. Systolic blood pressure decre-
ased below 60 mmHg necessitating 
multi-agent hemodynamic support with 
dopamine, dobutamine and noradre-
naline. Though auscultation of the chest 
revealed rales, cardiac auscultation and 
electrocardiogram were both normal. 
While invasive monitoring was initia-
ted, a panel of investigations was orde-
red immediately. Fluid overload was 
ruled out by a normal central venous 
pressure (CVP=6cmH2O) and normal 
echocardiography signs (EF – ejection 
fraction = 70 %). Additionally, the pati-
ent did not have any clinical signs such 
as juguler venous distension, systolic 
hypertension or S3 gallop and angioe-
dema, wheezing, stridor or urticaria. The 
laboratory findings include leukopenia 
(White Blood Cell [WBC]: 1.5 K.uL-1), 
neutropenia (35%) and monocytopenia 
(1.1%), additionally C-reactive protein 
(CRP) and procalcitonin (PCT) levels 
were not increased. Re cross-match 
performed was also negative. 
Initial resuscitation procedures com-
prised MV, hemodynamic support with 
multi-agents, iv fluids with both crystallo-
id and colloid and drugs routinely used 
in our clinic (Asist® 4×300 mg,etc). Her 
arterial SBP increased from 60 mmHg 
to more than 80 mmHg after approxi-
mately 2 hrs. When  the WBC count was 
measured at 4th hr, the leukocyte count 
(WBC: 7.4 K.uL-1), neutrophile (71.1%), 
monocyte (5.5%) was normalized. Over 
a period of 5 hrs, the patient began to 
respond the symptomatic measures. 
Her hemodynamic parameters impro-
ved and the vasopressor support could 
be withdrawn after 12 hrs. 
The result of the HLA typing of posttran-
sfusion blood sample was taken from 2 
days after transferring to the laboratory. 
HLA typing and tests for Panel Reac-
tive Antibody (PRA) were performed 
by Luminex method (PRA, Luminex, 
Tepnel, USA). After the transfusion, the 
patient had multiple anti-HLA antibodi-
es to HLA class II antigens (Anti-DR11, 
Anti DR12, Anti DR13 and Anti DR16 
and % PRAs of the patient’s serum 
was 66 %). Based on the clinical signs 
and laboratory findings including the 
presence of patient’s anti-HLA class 
II antibodies which potentially could 
have reacted with donor’s leukocyte 
antigens, the diagnosis of TRALI was 
become definite.
Recovery from the pulmonary insult 
was not slower, her chest radiography 
showed clearance of pulmonary infiltra-
tes in the third day of ventilatory support 
(figure 2) and weaning was possible in 
the third day also. She was eventually 
recovered completely in the next days 
and discharged from the ICU by the 
5th posttransfusion day without any 
sequel. 
Discussion
Transfusion Related Acute Lung Injury 
is a complex clinical syndrome, it pro-
bably does not represent a simple 
pathogenic entity. There is increasing 
evidence that this reaction can be trig-
gered by two distinct mechanisms. 
(9-11) The subtypes of TRALI based 
on underlying mechanism into immune 
(antibody mediated, antiHLA/anti-HNA) 
or nonimmune (non-antibody media-
ted, biologically active lipids in stored 
blood component). (8-10) As shown in 
our patient, in the immune type TRALI 
develops as a result of an antigen-anti-
body reaction. 
In 60 % to 80 % of cases, antibodi-
es found in the donor’s blood product 
react with the recipient’s leukocytes; 
however in 5 % to 10 % of the cases, 
TRALI may develop as a result of anti-
bodies in the recipient reacting with 
the donor’s leukocytes in the reverse 
mechanism. It was thought that TRALI 
in our patient can be caused by leuko-
cyte antibodies in the patient’s serum 
against donor WBC antigens. The res-
ponsible immunoglobulin antibodies 
(Ig M/G) in the patient serum bind and 
stimulate the small number of circula-
ting leukocytes of the transfused blood 
have also been described in several 
studies. (1,9,10) Anti-HLA antibodies 
do not occur naturally but as a result of 
immunologic challenge with previous 
transfusion or pregnancy histories may 
be the reasons of TRALI in our patient. 
TRALI has traditionally been associated 
with the infusion of anti-HLA class I anti-
bodies. However, TRALI caused by anti 
HLA class II antibodies without simul-
taneous presence of anti-HLA class I 
antibodies have rarely been described. 
In recent report, it has been suggested 
that anti HLA class II antibodies play a 
critical role in initiating TRALI develo-
pment. (12) In our case, it has not been 
showed the presence of anti-HLA class 
I antibodies so our case supports the 
role of anti HLA class II antibodies alone 
as the cause of TRALI here.
Although the diagnosis of TRALI is pri-
marily clinical and radiographic, (5) it is 
important to  differentiate TRALI clini-
cally from transfusion associated cardi-
ac overload (TACO) and other transfu-
sion reactions like allergic/anaphylactic 
reactions and bacterial contamination 
of the transfused blood product. (13) 
Like TRALI, TACO is increasingly being 
rediscovered as a common complica-
tion of transfusion. TACO is defined by 
a combination of clinical signs such as 
tachypnea/respiratory distress, cyano-
sis, tachycardia, juguler vein distensi-
on, post-transfusion hypertension and 
S3 gallop on cardiac examination. (13) 
Elevated CVP/PAOP, pulmonary edema 
with cardiomegaly on chest radiograp-
hy and prompt response to diuretics 
are more consistent with TACO. (14) 
The CVP and wedge pressures are typi-
cally low or normal in TRALI but may be 
elevated if TRALI occurs in the setting 
of heart failure. (10, 15) Therefore, it is 
important to show the normal ECHO 
signs and CVP/PAOP (pulmonary artery 
occlusion pressures) in these patients. 
In our patient CVP was within normal 
range (CVP=6cmH2O) but we did not 
measure the wedge pressures. Inserti-
 55www.signavitae.com
on of pulmonary artery catheter is not 
without risk, and because of its limited 
sensitivity and specificity and also infec-
tion risk we did not insert the pulmonary 
arthery catheter. Moreover, both hypo-
tension and rarely hypertension may 
be seen in TRALI. (10,12) The hypoten-
sion may be unresponsive to iv fluids 
nevertheless in the presence of normal 
cardiac function as seen in our patient 
and she was in need of adminstrating 
vasopressor support. Also, both pro-
duction of clear frothy fluid secretions 
and increased airway pressure have 
been noted in TRALI and besides two 
of them were shown in our patient. The 
ECHO evaluation of the patient was 
shown that the left ventricule diameter 
was 4.9 cm, EF was 70% and no other 
heart wall motion defects was deno-
ted also. Though it has been reported 
that B-type Natriuretic Peptide (BNP) 
has some value in distinguishing TACO 
from TRALI, (16) Zhou et al. demon-
strated 81% sensitivity, 89% specificity, 
89% positive and 81% negative predic-
tive value and 87% accuraccy of BNP (B 
type natriuretic peptide) in diagnosing 
TACO (16). In any case, we could not 
measure the level of this hormone in our 
hospital at that time. But taken together, 
we thought that clinical manifestations 
such as normal range of CVP, normal 
echocardiographic signs (normal LV 
cavity size and LV ejecion fraction), 
hypotension and nonappearance of the 
juguler vein distension, post-transfusion 
hypertension and S3 gallop on physical 
examination strongly supports TRALI 
and help us to exclude of TACO existen-
ce in our patient. Since there were no 
angioedema, wheezing, stridor or urtica-
ria over the neck and trunk, the diagno-
sis of anaphylactic transfusion reaction 
was also excluded.  Moreover, the res-
piratory distress from anaphylactic reac-
tion is related to laryngeal and bronchial 
edema rather than pulmonary edema 
so the chest radiograph will generally 
be clear in anaphylactic reaction to the 
opposite of TRALI. (14,17) Acute hemo-
lytic reaction has been excluded based 
on repeated cross-match results and 
absence of typical clinical features such 
as hemoglobinuria or renal failure. (17) 
The transfusion of contamined blood 
products may also result in transfusi-
on-related bacterial sepsis that manife-
sts as fever, hypotension and vascular 
collapse and these patients may also 
experience ALI. (17) To differentiate this 
condition, the culturing the component 
bags and evaluate the WBC, CRP and 
PCT levels must be assessed also. 
The coexistence of the leukopenia and 
absence of not only increased level of 
CRP and PCT but also  hemoglobinuria 
or renal failure were also chased us from 
the other possibilities. 
However, there are no specific labora-
tory markers to confirm TRALI, the only 
routine laboratory parameter that has 
been associated with TRALI is leuko-
penia, especially neutropenia. (7,18) It 
has been an infrequent finding in most 
of the published cases of TRALI. Naka-
gawa and Toy (18) found that the pati-
ents have a transient, marked decrease 
in the WBC count where the leukocyte 
count normalized between 1.5 and 7.5 
hours after reaching its nadir. They 
also noted neutropenia in all cases, 
even those associated only with anti 
HLA class II antibodies. This dynamic 
leukopenia could add support to the 
diagnosis of TRALI, as it would not be 
expected to occur in cardiogenic pul-
monary edema or TACO. Alike, addition 
to the other clinical features, leukopenia 
in our patient speculated the accuracy 
of our diagnosis because she had neu-
tropenia which was normalized after 4 
hrs from the transfusion. 
The treatment of both classic and 
delayed TRALI is primarily supportive 
and resembles the other forms of ALI. 
(8) The fundamental part of the trea-
tment is supplemental oxygen. (13,19) 
Though supportive treatment may be 
sufficient in mild cases, iv fluids, vaso-
pressor agents and MV may be required 
in severe TRALI. A low tidal volume, lung 
protective strategy has been advised 
for these patients. (4,19) The resolution 
of TRALI frequently occurs rapidly and 
most cases present a favorable evolua-
tion without any sequele. (2,4,13) In our 
case, it was thought that severe TRALI 
was managed with both iv fluids, vaso-
pressor agents for intractable hypotensi-
on and lung protective MV and she was 
discharged without any sequele.
In conclusion, correct diagnosis and 
treatment are very important in TRALI. 
The keys to the diagnosis of TRALI 
are high clinical suspicion, differenti-
ation the other possibilities of ALI or 
Acute Respiratory Distress Syndrome 
(ARDS), radiological, biochemical and 
immunological findings. Also TRALI can 
be developed because of antibodies 
found in the donor’s blood product, it is 
necessary to know that it may develop 
as a result of antibodies in the recipi-
ent reacting with the donor’s leuko-
cytes in the reverse mechanism. We 
thought that, in the cases which TRALI 
associated only with anti HLA class II 
antibodies, it is important to minimize 
the risks for infection becuse of the 
relationship between anti HLA class 
II antibodies and leukopenia, which 
might be associated with patient and 
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